Novartis raises annual profit outlook after strong Q3 sales growth
Novartis AG (NOVN) raised its full-year core operating income outlook due to Q3 sales growth and margin expansion. Net sales rose 4% to $14.52B, while core operating income increased 11% to $6.04B. Growth was driven by drugs like Kisqali, Kesimpta, and Scemblix. However, reported operating income fell 59% to $1.84B due to a $1.9B impairment charge. The company maintained low single-digit sales growth guidance.
How this was made
The 30-second read
Why it matters
The guidance lift is a fresh, material development for a large‑cap pharma, likely prompting price appreciation.
Market read
First‑report guidance upgrade for a major pharma; high relevance for traders.
What to watch
The $1.9 bn impairment could weigh on near‑term profitability despite the outlook upgrade.
Background
Novartis reported Q3 sales up 4% to $14.52 bn, with strong performance from Kisqali, Kesimpta, Scemblix and Leqvio, while net income fell due to a $1.9 bn impairment.
Ticker impact
Novartis raised its full‑year core operating income outlook to flat or low‑single‑digit growth, upgrading from a low‑single‑digit decline.
likely upside as investors price in higher operating income expectations
The outlook change is material for a large‑cap pharma and is the first report of the upgrade, prompting immediate market reaction.
Market effects
May lift broader healthcare and pharma stocks as peers are re‑rated.
Supports European markets, especially Swiss listings.
Adds to global earnings momentum, could influence risk‑on sentiment.
Counterpoint
Some investors may question the sustainability of growth given the large impairment charge.
Key entities
- companyNovartis AG
Swiss pharmaceutical giant reporting Q3 results and raising full‑year outlook.
